权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of a novel imaging modality for adoptive cell therapy

开发用于过继细胞治疗的新型成像方式

基本信息

批准号：
10316427
负责人：
Agata A Exner
金额：
$ 41.4万
依托单位：
CASE WESTERN RESERVE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-17 至 2023-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10316427
关键词：
Acoustics Activated Natural Killer Cell Acute Lymphocytic Leukemia Adoptive Cell Transfers Antibodies Area B lymphoid malignancy Blood CD19 gene Cell Surface Receptors Cell Therapy Cells Cellular immunotherapy Clinical Clinical Trials Colon Carcinoma Colonic Neoplasms Contrast Media Cytolysis Development Disease remission Dose Exhibits FDA approved Future Genetic Engineering Human Image Immune Knowledge Label Lead Ligands Lymphocyte Subset Malignant Neoplasms Measurement Mesenchymal Stem Cells Methodology Methods Microbubbles Modeling Monitor Mus NK cell therapy Natural Killer Cells Patients Peptides Pharmacotherapy Public Health Refractory Refractory Disease Relapse Safety Signal Transduction Solid Neoplasm T-Lymphocyte Technology Testing Therapeutic Tissues Translating Ultrasonography Work base cancer cell cancer clinical trial cancer therapy chimeric antigen receptor chimeric antigen receptor T cells clinical implementation cohort detection sensitivity engineered T cells human imaging human tissue imaging modality improved in vivo interest metastatic colorectal mouse model nanobubble nanoscale new technology non-invasive monitor novel novel therapeutic intervention preclinical development pressure receptor refractory cancer research clinical testing response submicron success technology validation trafficking treatment optimization tumor uptake

项目摘要

Abstract: Recently a new therapeutic approach for cancer has exhibited high promise termed adoptive cell therapy. This approach involves treating patients with immune cells such as T cells or Natural Killer (NK) cells instead of drug therapy. While some cell therapies have exhibited high promise for at least a subset of cancers, a major technological challenge in the development of this field is the lack of knowledge of where these cells reside in the body once they are infused. While it is readily easy to monitor the blood for the presence of the infused immune cells, there is no satisfactory method to monitor the cells that traffic into tissue (ex. colon tumors). In this proposal, we will develop a novel method to label immune cells using nanobubbles (NBs). These labelled cells then can be monitored non-invasively using an ultrasound. As NBs are a component of an already FDA approved product, we anticipate this approach will not only be safe but can be translated quickly to human testing. It is hoped that this work will lead to new technology that will enable us to monitor the trafficking of immune cell therapies so that we can optimally select which patients/tumor types would most benefit from a given cell therapy product.

文摘: